07
Jun
Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma. Krieger1 and Myron E.
Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation.
Hepatocellular carcinoma recurrence after liver transplant. Liver transplantation LT is the treatment of choice for patients with unresectable early hepatocellular carcinoma HCC. Post-LT HCC recurrence rates range from 8 to 20 and still impact on overall survival OS. The aim of our study was to evaluate the impact of HCC recurrence on post-LT survival and analyze prognostic factors among those patients with recurrence.
Outcome after liver transplantation OLT clearly depends on recurrence of hepatocellular carcinoma HCC. After recurrence patient outcome will depend on the time and site of appearance. The aim of this study was to analyze the therapeutic implications of tumor recurrence behavior.
From October 1988 to December 2005 685 patients received OLT including 202 due to HCC 32. We analyzed 28 recurrences. Recurrence of Hepatocellular Carcinoma After Liver Transplant.
Patterns and Prognosis Sasan Roayaie1 Jonathan D. Krieger1 and Myron E. Hepatocellular Carcinoma Recurrence After Liver Transplantation Key Points.
A 64-year-old white woman with hepatitis C virus HCV infection-related well-compensated cirrhosis. In patients within the Milan criteria bridging therapies such as TACE or ablation are advisable. Schnitzbauer AA Schlitt HJ Geissler EK.
Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation. A gap between basic science and clinical evidence. Rodríguez-Perálvarez M De la Mata M Burroughs AK.
Curr Opin Organ Transplant. OLT is currently the best available treatment for nonresectable HCC improving 5-year survival from 10 in untreated HCC patients to 70. 1 However recurrence is common and poor outcomes are particularly associated with early recurrence within 2 years of transplantation.
2 A retrospective cohort analysis found that 16 of recipients experience HCC recurrence most within 2 years with an overall survival after recurrence of 13 months. 3 Among patients experiencing recurrence. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation Hepatobiliary Pancreat Dis Int.
Combined hepatocellular carcinoma and cholangiocarcinoma cHCC-CC is commonly diagnosed as hepatocellular carcinoma HCC preoperatively. Therefore unexpected recurrence occurs in some patients after liver transplantation LT. Carcinoma after liver transplantation.
Still an unmet need 1 INTRODUCTION Recurrence of hepatocellular carcinoma HCC after liver transplanta-tion LT is a frightening issue. It is considered a systemic advanced stage with poor survival rate from the time of its diagnosis with few therapeutic treatment resources because of its metastatic nature. Initially in the early 1980s the survival.
Carcinoma After Liver Transplantation Shunji Nagai12 Atsushi Yoshida2 Marcelo Facciuto1 Dilip Moonka3 Marwan S. Schwartz1 and Sander S. Florman1 Although experimental evidence has indicated that ischemia-reperfusion IR injury of the liver stimulates growth of micrometastases and adhesion of tumor cells the clinical impact of IR injury on recurrence of.
The recurrence of HCC after liver transplantation is notoriously difficult to manage. We hereby propose multi-disciplinary management with a systematic approach. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma.
A proposed management algorithm World J Gastroenterol. Authors Kin Pan Au. Hepatocellular carcinoma HCC has been well studied with the aim of determining which characteristics predict recurrence and survival after liver transplant.
1-3 Analysis of the data from the International Registry of Hepatic Tumors in Liver Transplantation has demonstrated that 255 of the 422 patients transplanted with HCC have had recurrence of their tumor. 1 More recent studies using better. Liver transplantation LT provides an excellent option for the long-term survival of patients with unresectable hepatocellular carcinoma HCC based on the Milan criteria.
Despite careful selection of patients HCC may still recur after LT which represents the most important negative predictor of post-transplant survival. Recurrence of hepatocellular carcinoma HCC after liver transplantation LT is widely considered as a terminal condition. Therefore the role of surgery is uncertain in this case.
The purpose of this study was to identify the prognostic factors of survival after postLT HCC recurrence and to evaluate the impact of surgery in this setting. All patients transplanted for HCC between 1991 and. I read with interest the 2-center experience on sorafenib treatment for recurrent hepatocellular carcinoma HCC after liver transplantation LT.
1 The study reports retrospective data on 50 cases ¾ of whom were treated with mammalian target of rapamycin inhibitor mTORi describing a high rate of severe adverse events grade 34 in more than half of the cases. In western countries hepatocellular carcinoma HCC is a major reason for orthotopic liver transplantation OLT with estimated recurrence rates between 15 and 20. This selective literature review addresses followup care after OLT in HCC and current treatment options.
It is well known that the presence of end-stage liver disease increases the risk of developing hepatocellular carcinoma HCC. Liver transplantation LT for patients within the Milan criteria has become a standard treatment for HCC in most developed centers worldwide. However a major cause of death in cirrhotic patients with HCC after transplantation is tumor recurrence including peritoneal.
Post-liver transplantation LT hepatocellular carcinoma HCC recurrence still occurs in approximately 20 of patients and drastically affects their survival. This study aimed to evaluate the efficacy of various treatments for recurrent HCC after LT in a Chinese population. A total of 64 HCC patients with tumor recurrence after LT were enrolled in this study.